# Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

> **NCT02345070** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 327 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** SAR156597
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02345070
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2017-05-22
- **Final completion:** 2017-08-14
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345070, "Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02345070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*